Cannabix Advances Multi-Drug Breath Testing
VANCOUVER, British Columbia, July 6, 2026 Cannabix Technologies announced the successful detection of cocaine and its primary metabolite, benzoylecgonine,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
VANCOUVER, British Columbia, July 6, 2026 Cannabix Technologies announced the successful detection of cocaine and its primary metabolite, benzoylecgonine,...
VANCOUVER, British Columbia, July 8, 2026 Cannabix Technologies Inc. and Omega Laboratories announced the development and validation of a...
VANCOUVER, British Columbia, July 2, 2026 Cannabix Technologies Inc. announced the successful detection of methamphetamine and amphetamine compounds in...
